经皮股动脉植入动脉化疗泵灌注中西药治疗晚期肝癌疗效观察

目的：评价肝动脉经皮股动脉植入化疗泵灌注中西药治疗晚期原发性肝癌的临床疗效。方法：以生存期为观察指标,采用同期非随机对照方法,对2007年3月～2010年10月接受经皮股动脉植入动脉化疗泵灌注中西药的16例中晚期原发性肝癌患者（治疗组）与对症营养支持治疗的16例患者（对照组）比较,观察两组的生存期缓解差异。结果：治疗组与对照组中位生存期分别为20个月（6～29）、4个月（2～8）,治疗组生存期长于对照组（P〈0.05）。结论：经皮股动脉植入化疗泵灌注中西药能提高中晚期原发性肝癌患者的远期生存率,提高患者生存质量,延缓肝癌复发进展,延长患者的生命。

Effects observation on treating advanced liver cancer by percutaneous femoral artery implanted arterial chemotherapy plus pump infuse integrative medicine

Objective：To evaluate the clinical effect of treating advanced liver cancer percutaneous femoral artery implanted arterial chemotherapy plus pump infuse TCM and Western medicine.Methods：With survival as index,applying corresponding time period non-randomized comparison methods to compare 16 cases of patients with advanced primary liver cancer（treatment group）who received percutaneous femoral artery implanted arterial chemotherapy plus pump infuse TCM and Western medicine with 16 cases of patients with symptomatic treatment of nutritional support（control group）,then observe survival ease differences between the two groups.Results：The median survival in treatment group and control group were 20 months（6～29）,4 months（2～8）,survival time in treatment group was longer than control group（P0.05）.Conclusion：Percutaneous femoral artery implanted arterial chemotherapy plus pump infuse TCM and Western medicine could improve long-term survival rate of patients with advanced primary liver cancer and QOL of patients,delay the progress of liver cancer recurrence and prolong the lives of patients.